AdjuCor GmbH Launches European Union Co-Funded Project "Biventricular Epicardial Augmentation Technology (Project 190170931)" for Accelerating Market Entrance of reBEAT, their Innovative Cardiac Support Device
MUNICH, Feb. 3, 2023 /PRNewswire-PRWeb/ -- AdjuCor GmbH, an innovative medical device company based in Munich, Germany, is proud to announce the start of their European Union (EU) co-funded project for their revolutionary cardiac support device, reBEAT. This project represents a significant milestone in the company's mission to improve patient outcomes and enhance the quality-of-life for those suffering from advanced heart failure.
The new cardiac support device, reBEAT, aims to revolutionize the treatment of advanced heart failure, since it is capable for providing biventricular mechanical circulatory support (BiV-MCS) that completely avoids direct blood contact. reBEAT is set to transform the space in treatment, since patients that would benefit from receiving a heart transplantation are very limited due to the world-wide organ donor scarcity. Furthermore, the only current alternative treatment are MCS treatments, e.g. left ventricular assist devices (LVADs), which are associated with many complications related to blood-contact.
The EU grant funding of €2.5 million over the next 2 years will aid AdjuCor to progress through its clinical evaluation phase in Europe, in order to bring this game-changing technology to market. The project will involve clinical trials, device optimization, and regulatory approval processes to ensure that the device is safe and effective for patients.
AdjuCor's CEO, Prof. Stephen Wildhirt, expressed his excitement for the upcoming project, stating, "We are thrilled by the support from the EU that will allow us to bring our vision to a clinical reality. We look forward to seeing the positive impact this device will have on the lives of those in need."
AdjuCor is committed to develop innovative medical devices that improve patient outcomes and enhance the quality of life. The company is confident that their new cardiac support device, reBEAT, will have a profound impact on the treatment of heart failure and is excited to take this important step forward with the support of the EU.
About reBEAT – AdjuCor's Innovative Extravascular, Biventricular Cardiac Support Technology
The reBEAT system contains AdjuCor's patented technologies that is set apart from the LVADs and total artificial hearts(TAHs) currently available on the market. Featuring a unique non-blood-contacting solution, it can support both ventricles, and comprises an innovative patient-specific design. It can be implanted by a heart team (cardiologist and surgeon) within a few minutes on the beating heart without sutures. reBEAT completely avoids blood contact and thereby any blood-related complications including strokes and bleeding – an invaluable advantage that cannot be over-stated. It is thereby set to dramatically enhance the care of patients with end-stage heart failure and improve their quality of life.
About AdjuCor
AdjuCor is based in Munich, Germany and was founded as a GmbH in 2012 by the cardiothoracic surgeon, Prof. Stephen Wildhirt. It has been funded by private investors, the European Union, as well as German and Bavarian entities. The company employs over thirty-five experts in multiple disciplines. With this new funding round, it has now raised over € 42 million in total of financing.
About EIC
The European Innovation Council (EIC) is Europe's flagship innovation programme that provides funding and support for high-impact projects in the fields of technology and innovation. The EIC supports projects with the potential to create jobs, improve quality of life, and drive economic growth.
For more information, please visit: http://www.adjucor.com or contact [email protected]
Or follow us on LinkedIn: http://www.linkedin.com/company/adjucor
Disclaimer
Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or granting authority. Neither the European Union nor the granting authority can be held responsible for them.
Media Contact
Dr. Hamman de Vaal, AdjuCor GmbH, 49 89262049600, [email protected]
SOURCE AdjuCor GmbH
Share this article